ArticleClinicoEconomics and outcomes research : CEOR2026
Economic Burden of treated Lower-Risk Myelodysplastic Syndromes in France: A Population-Based Study.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Updated data are needed to understand the current implications of Low-risk Myelodysplastic syndromes (LR-MDS) on healthcare resource use (HCRU) and associated costs. Objectives of this study were to describe these outcomes over time but also to compare costs according to transfusion dependency at baseline. Methods: A retrospective observational study was carried out using the ESND ("Echantillon National du SNDS") database. All incident adults newly treated for MDS were included between 2018 and 2022. Patients were followed from the start of specific treatment to death, the end of the study period, or loss to follow-up (FU). HCRU and related costs were described according to French National Health Insurance perspective in euro 2022. Reimbursed total costs per patient were computed per year of follow-up and according to transfusion status. Results: Over the study period, 267 patients newly treated for LR-MDS were included. Median total costs related to HCRU/patient for the entire FU period were estimated at €41,698 (IQR: 19,093; 84,111) with a median cost/patient/year of FU ranging from €26,693 (Y1) to €20,418 (Y3). Main cost drivers were hospitalizations and use of specific drugs. TD patients had more hospitalizations (94.4% vs 89.3%) and transfusions (77.5% vs 47.4%), leading to statistically significantly higher costs after treatment initiation. Conclusion: This nationwide study is the largest describing the economic burden of treated LR-MDS patients in France using administrative claims data. Elevated costs and substantial burden for treated patients and the health care system were observed. Transfusion dependence was associated with incremental health care resource utilization and related costs. Further studies are needed to assess the impact of emerging therapies in this indication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.